Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Nine Patients Received a Personalized Kidney Cancer Vaccine. None Had a Recurrence. : ScienceAlert (opens in a new tab)

Nine Patients Received a Personalized Kidney Cancer Vaccine. None Had a Recurrence. · 2026-10-01

Short answerEvidenceSource

Short answer

Supported

Supported.

The story matches what the study reports.

  • 4 supported

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1

The story

Nine Patients Received a Personalized Kidney Cancer Vaccine. None Had a Recurrence. : ScienceAlert

Nine Patients Received a Personalized Kidney Cancer Vaccine. None Had a Recurrence. · 2026-10-01

The story’s checkable claims.

Read the original story (opens in a new tab)
2

NewsLink checks it

Supported

Every claim holds up. All four claims match what the study reports.

  • 4 supported
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4SupportedIn a small kidney cancer trial, nine people received an experimental vaccine tailored to their own tumors.View evidenceHide evidence

As statednine people

Why this verdict

The abstract-profile evidence describes a phase I trial of a personalized neoantigen-targeting vaccine in 9 patients with fully resected clear cell renal cell carcinoma, administered after surgery. The story’s framing as a small trial in nine people receiving a tumor-tailored experimental vaccine is consistent with this evidence.

1

Study evidence

No recurrences observed among 9 participants at a median follow-up of 40.2 months after surgery.0/9 recurrences; median follow-up 40.2 months

“Here we conducted a phase I trial (ClinicalTrials.gov identifier NCT02950766) to test a neoantigen-targeting PCV in patients with high-risk, fully resected clear cell renal cell carcinoma (RCC; stage III or IV) with or without ipilimumab administered adjacent to the vaccine.”
Claim 2 of 4SupportedNone of the nine patients experienced a recurrence during a median follow-up of roughly three years and four months after surgery.View evidenceHide evidence

As statedmedian follow-up of roughly three years and four months

Why this verdict

The paper profile reports that at a median follow-up of 40.2 months after surgery, none of the 9 enrolled participants had a recurrence of RCC. 'Roughly three years and four months' accurately corresponds to 40.2 months.

1

Study evidence

No recurrences observed among 9 participants at a median follow-up of 40.2 months after surgery.0/9 recurrences; median follow-up 40.2 months

“Here we conducted a phase I trial (ClinicalTrials.gov identifier NCT02950766) to test a neoantigen-targeting PCV in patients with high-risk, fully resected clear cell renal cell carcinoma (RCC; stage III or IV) with or without ipilimumab administered adjacent to the vaccine.”
Claim 3 of 4SupportedAll nine developed immune responses to the vaccine, and in seven cases vaccine-reactive T cells could also recognize the patient's own tumor.View evidenceHide evidence

As statedall nine; seven

Why this verdict

The profile states that all 9 patients generated T cell immune responses against the vaccine antigens, and that T cell reactivity against autologous tumours was detected in 7 of 9 patients. The story’s claim matches these abstract-level findings.

1

Study evidence

All nine vaccinated patients generated circulating T cell responses against the personalized vaccine antigens, including responses directed at RCC driver mutations (VHL, PBRM1, BAP1, KDM5C, PIK3CA).

“All patients generated T cell immune responses against the PCV antigens, including to RCC driver mutations in VHL, PBRM1, BAP1, KDM5C and PIK3CA.”
2

Study evidence

T cell reactivity against autologous tumours was detected in 7 of 9 vaccinated patients using ex vivo assays with patient-derived tumour material and post-vaccination T cells (abstract statement).7/9 patients (78%)

“Moreover, T cell reactivity against autologous tumours was detected in seven out of nine patients.”
Claim 4 of 4SupportedThe article says these findings do not yet prove that vaccination prevented the cancer from returning.View evidenceHide evidence

Why this verdict

The paper profile’s limitations state that the small phase I cohort and lack of randomized control/comparator group preclude conclusions about clinical efficacy. The story appropriately says the findings do not yet prove vaccination prevented recurrence.

1

Study evidence

No recurrences observed among 9 participants at a median follow-up of 40.2 months after surgery.0/9 recurrences; median follow-up 40.2 months

“Here we conducted a phase I trial (ClinicalTrials.gov identifier NCT02950766) to test a neoantigen-targeting PCV in patients with high-risk, fully resected clear cell renal cell carcinoma (RCC; stage III or IV) with or without ipilimumab administered adjacent to the vaccine.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Study population was high-risk, fully resected clear cell RCC, stage III or IV.

    The story notes clear cell renal cell carcinoma and surgery, but does not reflect the high-risk stage III/IV eligibility, which is material to interpreting recurrence risk and generalizability.

    From Phase I clinical trial (adjuvant, resected high-risk clear cell RCC)

  • Durable expansion of peripheral T cell clones after vaccination was observed.

    The story mentions immune responses but does not separately report the paper’s durable peripheral T cell clonal expansion finding.

    From Phase I clinical trial (adjuvant personalized neoantigen vaccine, with/without ipilimumab)

8 things the story did carry across
  • Phase I adjuvant trial of a personalized neoantigen-targeting vaccine after complete resection of clear cell renal cell carcinoma.
  • Nine participants were enrolled/treated and none had recurrence at median 40.2-month follow-up after surgery.
  • The vaccine was administered with or without adjacent ipilimumab, creating a co-intervention/subgroup issue.
  • Primary phase I emphasis on safety/tolerability, including dose-limiting toxicity; no dose-limiting toxicities were observed in the abstract profile.
  • All patients generated vaccine-specific T cell responses, including responses to RCC driver mutations.
  • T cell reactivity against autologous tumour was detected in 7 of 9 patients, based on ex vivo assays.
  • Small cohort and single-arm/no-comparator phase I design limit efficacy conclusions about whether the vaccine prevented recurrence.
  • Larger studies are needed to evaluate long-term efficacy and safety and compare outcomes with current standard care.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoEvaluate safety and preliminary clinical activity of a personalized neoantigen vaccine (with or without adjacent ipilimumab) as adjuvant therapy after complete resection of high-risk clear cell RCC.Phase I clinical trial (adjuvant, resected high-risk clear cell RCC)Expand

In plain English

Phase I adjuvant trial (NCT02950766) of a personalized neoantigen-targeting vaccine in 9 patients with fully resected high-risk (stage III/IV) clear cell renal cell carcinoma, administered with or without adjacent ipilimumab. At a median follow-up of 40.2 months there were no recurrences and no dose-limiting toxicities. All patients mounted vaccine-specific T cell responses, including responses that recognized reported RCC driver mutations (VHL, PBRM1, BAP1, KDM5C, PIK3CA); durable peripheral T cell clonal expansion was observed and T cell reactivity against autologous tumour was detected in 7 of 9 patients. The authors conclude the vaccine is highly immunogenic, can target driver mutations and can induce antitumour immunity in this cohort.

Key findings

  • No recurrences observed among 9 participants at a median follow-up of 40.2 months after surgery.0/9 recurrences; median follow-up 40.2 months
  • No dose-limiting toxicities were observed following vaccination (with or without adjacent ipilimumab) in this cohort.0/9 dose-limiting toxicities reported
“Here we conducted a phase I trial (ClinicalTrials.gov identifier NCT02950766) to test a neoantigen-targeting PCV in patients with high-risk, fully resected clear cell renal cell carcinoma (RCC; stage III or IV) with or without ipilimumab administered adjacent to the vaccine.”
What this piece can’t prove
  • Small cohort (n=9) from a phase I trial limits ability to draw conclusions about clinical efficacy.
  • Long-term efficacy and safety beyond the reported median follow-up require evaluation in larger studies.

2 further details could not be confirmed from the summary.

2human in vivoDetermine whether vaccination elicits circulating neoantigen-specific T cell responses, including responses to RCC driver mutations, and whether it expands durable peripheral T cell clonotypes.Phase I clinical trial (adjuvant personalized neoantigen vaccine, with/without ipilimumab)Expand

In plain English

In a phase I adjuvant trial of a personalized neoantigen vaccine (PCV) in nine patients with high-risk, fully resected clear cell RCC, all participants generated circulating T cell responses to vaccine antigens, including responses specific to reported RCC driver mutations (VHL, PBRM1, BAP1, KDM5C, PIK3CA). Vaccination was associated with durable expansion of peripheral T cell clones and detection of T cell reactivity against autologous tumours in 7/9 patients. Assay details and quantitative effect sizes are not provided in the abstract; some participants received ipilimumab adjacent to vaccination.

Key findings

  • All nine vaccinated patients generated circulating T cell responses against the personalized vaccine antigens, including responses directed at RCC driver mutations (VHL, PBRM1, BAP1, KDM5C, PIK3CA).
  • Vaccination was associated with a durable expansion of peripheral T cell clones.
“All patients generated T cell immune responses against the PCV antigens, including to RCC driver mutations in VHL, PBRM1, BAP1, KDM5C and PIK3CA.”
What this piece can’t prove
  • Small sample size reported in abstract (n = 9), limiting precision and generalizability.
  • Abstract lacks specification of the assays, readouts, thresholds, and quantitative effect sizes for neoantigen-specific T cell responses and clonotype tracking.
  • Some participants received ipilimumab adjacent to vaccination, which may confound attribution of immune responses solely to the vaccine.
  • Open-label, single-arm phase I design reported in abstract; no contemporaneous control group described.
3ex vivo humanTest whether vaccine-induced T cells can recognize and react against each patient’s autologous tumour (evidence of antitumour immunity).Ex vivo autologous tumour-T cell reactivity assay (functional)Expand

In plain English

Using ex vivo assays with patient-derived tumour material and post-vaccination T cells, the study reports that T cell reactivity against autologous tumours was detected in 7 of 9 vaccinated patients, indicating vaccine-induced T cells can recognize patients' own tumour cells in vitro.

Key findings

  • T cell reactivity against autologous tumours was detected in 7 of 9 vaccinated patients using ex vivo assays with patient-derived tumour material and post-vaccination T cells (abstract statement).7/9 patients (78%)
“Moreover, T cell reactivity against autologous tumours was detected in seven out of nine patients.”
What this piece can’t prove
  • Limited methodological detail in abstract: assay type, controls, positivity criteria and timing are not provided.
  • Small cohort (9 patients) — estimate of 7/9 has wide uncertainty.
  • Ex vivo recognition may not translate directly to antitumour activity in vivo.
  • Potential selection bias: all participants were resected, high-risk RCC patients enrolled in a phase I trial; generalizability unclear.
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 15 candidate papers

And 9 more candidates considered.